[NF-κB activity in myeloid leukemia stem cells]
- PMID: 25971268
- DOI: 10.11406/rinketsu.56.384
[NF-κB activity in myeloid leukemia stem cells]
Abstract
Acute myeloid leukemia (AML) is a hematologic malignancy which originates from leukemia initiating cells (LICs). Since LICs are considered to be resistant to standard chemotherapy, the identification of common mechanisms involved in LIC maintenance and progression is crucial to establishing broadly effective therapeutic agents for AML. The NF-κB pathway is one of the most promising targets, considering that its constitutive activation has been reported in different types of AML. In myeloid leukemia mouse models, we found that NF-κB activity is maintained specifically in LICs through autocrine TNF-α secretion, forming an NF-κB/TNF-α positive feedback loop. LICs had increased levels of active proteasome machinery, which promoted the degradation of IκBα and further supported NF-κB activity. Genetic ablation of TNF-α or NF-κB markedly suppressed leukemia progression in vivo. These findings demonstrate that NF-κB/TNF-α signaling in LICs contributes to leukemia progression and provide a widely applicable approach for targeting LICs.
Similar articles
-
Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity.J Clin Invest. 2014 Feb;124(2):528-42. doi: 10.1172/JCI68101. Epub 2014 Jan 2. J Clin Invest. 2014. PMID: 24382349 Free PMC article.
-
Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.Cancer Res. 2010 Mar 15;70(6):2516-27. doi: 10.1158/0008-5472.CAN-09-3950. Epub 2010 Mar 9. Cancer Res. 2010. PMID: 20215516
-
Adenosine suppresses activation of nuclear factor-kappaB selectively induced by tumor necrosis factor in different cell types.Oncogene. 2003 Feb 27;22(8):1206-18. doi: 10.1038/sj.onc.1206184. Oncogene. 2003. PMID: 12606947
-
Transcription factor NF-κB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies.Curr Mol Pharmacol. 2010 Nov;3(3):98-122. doi: 10.2174/1874467211003030098. Curr Mol Pharmacol. 2010. PMID: 20594187 Review.
-
Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia.Crit Rev Oncog. 2009;15(1-2):1-41. doi: 10.1615/critrevoncog.v15.i1-2.10. Crit Rev Oncog. 2009. PMID: 20136626 Review.
Cited by
-
Halogenated boroxine increases propensity to apoptosis in leukemia (UT-7) but not non-tumor cells in vitro.FEBS Open Bio. 2023 Jan;13(1):143-153. doi: 10.1002/2211-5463.13522. Epub 2022 Nov 22. FEBS Open Bio. 2023. PMID: 36369656 Free PMC article.
-
RNA modification in normal hematopoiesis and hematologic malignancies.MedComm (2020). 2024 Oct 23;5(11):e787. doi: 10.1002/mco2.787. eCollection 2024 Nov. MedComm (2020). 2024. PMID: 39445003 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical